Abstract
Background The objective of this study was to compare gut microbiome diversity and composition in SARS-CoV-2 polymerase chain reaction (PCR)-confirmed positive patients whose symptoms ranged from asymptomatic to severe, versus PCR-negative exposed controls. Using a cross-sectional study design, we used shotgun next-generation sequencing (NGS) to evaluate microbiome composition and diversity in both patients with SARS-CoV-2 PCR-confirmed infections presenting to Ventura Clinical Trials for care from March 2020 through January 2021, and SARS-CoV-2 PCR-negative exposed controls. Patients were classified as being asymptomatic or having mild, moderate, or severe symptoms based on NIH criteria. Exposed controls were individuals with prolonged or repeated close contact with patients with SARS-CoV-2 infection or their samples, e.g. household members of patients or frontline healthcare workers. Microbiome diversity and composition were compared between patients and exposed controls and across patient subgroups at all taxonomic levels.
Results Compared with controls (n=20), severely symptomatic covid patients (n=28) had significantly less bacterial diversity (Shannon Index, P=0.036; Simpson Index, P=0.026), and covid positive patients overall had lower relative abundances of Bifidobacterium (P<0.0001), Faecalibacterium, and Roseburia, while having increased Bacteroides (P=0.0075). Interestingly, there was an inverse association between disease severity and abundance of Bifidobacterium.
Conclusions We hypothesize that low bacterial diversity and depletion of Bifidobacterium genera either before or after infection led to reduced pro-immune function, thereby allowing SARS-CoV-2 infection to become symptomatic. This particular dysbiosis pattern may be a susceptibility marker for symptomatic severity from SARS-CoV-2 infection and may be amenable to pre-, intra-, or post infection intervention.
Registration clinicaltrials.gov NCT04031469 (PCR -) and 04359836 (PCR+)
Competing Interest Statement
SH declares that she has pecuniary interest in Topelia Pty Ltd in Australia, and Topelia Pty Ltd in USA where development of COVID-19 preventative/treatment options are being pursued. She has also filed patents relevant to Coronavirus treatments. She is the Founder and owner of Microbiome research foundation, Progenabiome and Ventura Clinical Trials. TJB declares that he has pecuniary interest in Topelia Pty Ltd in Australia, and Topelia Therapeutics Inc. in USA developing COVID-19 preventative/treatment medications. He has also filed patents relevant to COVID-19 treatments. S. Dave declares she has corporate affiliation to McKesson Specialty Health / Ontada and North End Advisory, LLC. S. Dave is unaware of SARS-CoV-2 and microbiome projects and not directly involved in COVID-19 relevant projects at McKesson, but they may exist. AJP, JD and BDB have corporate affiliations to Progenabiome. EMMQ serves as a consultant to Precisionbiotics, Novazymes, Salix, Biocodex and Axon Pharma and has received research support from 4D Pharma.
Clinical Trial
NCT04031469
Funding Statement
No funding was received for this manuscript. Several authors were compensated or salaried by ProgenaBiome.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with ethical principles of the Declaration of Helsinki, the International Council for Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP), and was approved by the Ethical and Independent Review Services (https://www.eandireview.com/) Independent Review Board (IRB). All patients provided written informed consent to participate in the study and the study is registered as clinicaltrials.gov NCT04031469.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added Figure 3B.
Data Availability
Data available upon reasonable request from corresponding author, Dr. Sabine Hazan.
Abbreviations
- B
- (Bifidobacterium)
- CDC
- (Center for Disease Control)
- F
- (Faecalibacterium)
- GCP
- (good clinical practice)
- IBD
- (inflammatory bowel disease)
- ICH
- (International Council for Harmonisation)
- IL
- (interleukin)
- IRB
- (Independent Review Board)
- NGS
- (next generation sequencing)
- NIH
- (National Institute of Health)
- PCR
- (polymerase chain reaction)
- PPE
- (personal protective equipment)
- SARS-CoV-2
- (Coronavirus, COVID, COVID-19)
- TNF
- (tumour necrosis factor)